NMN amorphous solid dispersant and preparation method thereof

Abstract

The invention discloses an amorphous solid dispersant of beta-nicotinamide mononucleotide (NMN) and a preparation method of the amorphous solid dispersant. The method comprises the following steps: dissolving NMN serving as a raw material in water or alcohol, mixing with a polymer carrier material, and carrying out spray drying to obtain the powdery amorphous solid dispersant. The NMN amorphous solid dispersant disclosed by the invention can be used for foods and beverages, is beneficial to improving the stability of NMN and achieving a slow release effect, and is simple in preparation method and suitable for industrial production.

Description

Technical Field

[0001] This invention belongs to the field of health food, specifically relating to an NMN amorphous solid dispersant and its preparation method. Background Technology

[0002] Amorphous solid dispersions (ASDs) are products made by highly dispersing active ingredients in an amorphous form within a hydrophilic polymer carrier such as hydroxypropyl methylcellulose (HPMC), povidone (PVP), or hydroxypropyl methylcellulose acetate succinate (HPMCAS). The core mechanism of this preparation technology is to disrupt the crystalline structure of the active ingredient, forming a high-energy, highly soluble amorphous state, and then using the polymer to inhibit its recrystallization.

[0003] For poorly soluble drugs, ASD can significantly improve their solubility and dissolution rate, thereby improving their oral bioavailability and representing a key technology for solving the problem of "dissolution-limited absorption" in drugs. The physical stability of ASD is crucial; its amorphous state is thermodynamically metastable and tends to recrystallize spontaneously during storage. The properties of the ASD system are highly dependent on the chosen polymer carrier, which not only stabilizes and inhibits crystallization but also determines the preparation method (e.g., hot melt extrusion, spray drying), dissolution behavior, and storage conditions.

[0004] NMN, or β-nicotinamide mononucleotide, is a naturally occurring bioactive nucleoside and a vitamin B3 derivative. It is a key precursor to nicotinamide adenine dinucleotide (NAD⁺), which is converted to NAD⁺ via nicotinamide mononucleotide adenylate transferase. NAD⁺ participates in core physiological processes such as energy metabolism, DNA repair, and activation of longevity proteins.

[0005]

[0006] The human body can synthesize NMN itself and obtain it from small amounts of vegetables such as broccoli and avocado. As we age, the level of NAD⁺ in the body declines. Supplementing with NMN is believed to increase NAD⁺ levels, improve metabolism, delay cell aging, and has potential value in cardiovascular protection and neurological health maintenance. Because NAD⁺ is difficult for the body to absorb, NMN can be converted into NAD⁺ after entering the body. + Increase intracellular NAD + The concentration of NAD can help prevent and improve various health conditions caused by NAD deficiency.

[0007] NMN has poor stability and is prone to absorbing moisture and deliquescing, leading to accelerated decomposition. Additionally, its high water solubility results in a rapid release rate in the body. These characteristics limit the production and use of NMN, necessitating improvements in formulation. Summary of the Invention

[0008] To address the instability and rapid dissolution of NMN, we use NMN as a raw material, dissolving it in water, alcohol, or a mixture of both, then mixing it with specific polymer carrier excipients, and finally spray-drying it to obtain a powdered amorphous solid dispersion (ASD). Formulating water-soluble NMN into an ASD is a "functional formulation strategy" that helps improve NMN stability, achieve a sustained-release effect, and enhance processing performance. The resulting amorphous solid dispersion exhibits good wet-heat stability and a lower dissolution rate than NMN crystals, making it suitable for applications in the food and beverage industries. Specifically, this invention includes the following technical solutions.

[0009] The first aspect of the present invention provides an NMN amorphous solid dispersant (ASD), characterized in that its components substantially include food-grade or pharmaceutical-grade hydrophilic polymer powder particles as a carrier material and β-nicotinamide mononucleotide (NMN) embedded in the particles, more preferably the NMN amorphous solid dispersant (ASD) is substantially composed of food-grade or pharmaceutical-grade hydrophilic polymer powder particles as a carrier material and NMN embedded in the particles.

[0010] As used herein, the term "basic" refers to the fact that the NMN amorphous solids dispersant (ASD) includes, in addition to the hydrophilic polymer and NMN, residual auxiliaries essential for the preparation process or additives added for commercial purposes. The auxiliaries are selected from water or ethanol used to dissolve the hydrophilic polymer; the additives are selected from edible colorings or flavorings such as triethyl citrate.

[0011] In one embodiment, the hydrophilic polymer is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (PVP), Eudragit dispersion, and mixtures of two or more thereof.

[0012] Preferably, the hydroxypropyl methylcellulose (HPMC) is hydroxypropyl methylcellulose E5 (HPMC-E5); the povidone (PVP) is povidone K30 (PVP-K30); and the Eudragit dispersion is 70% Eudragit dispersion (Eudragit-70%).

[0013] Preferably, in the above-mentioned NMN amorphous solid dispersant, the weight ratio of NMN to hydrophilic polymer is 1:0.8-2.5, more preferably 1:1-2, more preferably 1:1-1.8, and even more preferably 1:1-1.5.

[0014] Preferably, the water content in the above-mentioned NMN amorphous solid dispersant is not higher than 5% by weight, more preferably not higher than 4.5%, and even more preferably not higher than 4%.

[0015] In one embodiment, the particle size of the above-mentioned NMN amorphous solid dispersant is not higher than 30 μm, preferably not higher than 25 μm, more preferably 0.5~22 μm, and even more preferably 1~20 μm; and / or

[0016] The particle size D50 of more than 50%, preferably more than 60%, more preferably more than 70%, more preferably more than 80%, and more preferably more than 90% is 1-6μm, preferably 1.5-5.5μm, and more preferably 2-5μm.

[0017] This particle size gives NMN amorphous solid dispersant particles good flowability, which is beneficial for product packaging and processing, and also helps maintain a good taste.

[0018] Preferably, the X-ray powder diffraction (XPRD) pattern of the above-mentioned NMN amorphous solid dispersant does not show obvious absorption peaks, thus maintaining the amorphous state of NMN.

[0019] A second aspect of the present invention provides a method for preparing the NMN amorphous solid dispersant as described above, characterized by comprising the following steps:

[0020] (1) Raw material preparation: Dissolve the hydrophilic polymer in water or an aqueous ethanol solution to obtain a hydrophilic polymer dilution;

[0021] (2) Raw material mixing: NMN is added to the hydrophilic polymer dilution solution, and commercially available additives are added if necessary. The mixture is then thoroughly mixed to obtain the final product.

[0022] (3) The mixture obtained in step (2) is formed into powder particles by spray drying device.

[0023] Optionally, in the above method, step (1) is to obtain a hydrophilic polymer dilution by homogenization treatment using a homogenizer; and / or step (2) is to obtain a mixture by homogenization treatment using a homogenizer.

[0024] In one embodiment, the spray drying temperature in the above method is not higher than 150°C, preferably not higher than 140°C, more preferably not higher than 135°C, and even more preferably not higher than 130°C.

[0025] A third aspect of the invention provides the use of the NMN amorphous solid dispersion as described above in the preparation of food, dietary supplements and / or pharmaceuticals.

[0026] Preferably, the above-mentioned foods, dietary supplements and / or medicines are used to prevent and improve unhealthy conditions caused by NAD deficiency.

[0027] This invention develops an amorphous solid dispersant for β-nicotinamide mononucleotide (NMN), which can maintain the physical and chemical stability of NMN, avoid NMN from absorbing water and deliquescence, thereby significantly extending the shelf life; and can better control the intestinal dissolution rate of NMN to achieve a moderate sustained-release effect, so that the human body can fully absorb NMN, prevent and improve the health conditions caused by NAD deficiency, and enhance the health and medical effects of NMN products. Attached Figure Description

[0028] Figure 1 This is an X-ray powder diffraction (XPRD) pattern of ASD prepared using NMN and HPMC-E5 in one embodiment of the present invention. The pattern confirms that NMN is an amorphous solid.

[0029] Figure 2 The image shows a scanning electron microscope (SEM, 200x magnification) image of ASD prepared using NMN and HPMC-E5 in one embodiment of the present invention, wherein the upper image is a 200x magnified image and the lower image is a 2000x magnified image. This image confirms that the NMN-based ASD exists as a highly dispersed and uniform powder.

[0030] Figure 3 This is a graph comparing the dissolution rate of ASD prepared from NMN and HPMC-E5 with NMN crystal form I in one embodiment of the present invention. The horizontal axis represents time (min), and the vertical axis represents the dissolution percentage (%). This graph confirms that the solubility and dissolution rate of ASD powder are lower than those of NMN crystals.

[0031] Figure 4 This is a comparison of differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) plots of ASD prepared using NMN and HPMC-E5 in one embodiment of the present invention. The horizontal axis represents temperature (°C); the left vertical axis represents heat flow (W / g), and the right vertical axis represents weight percentage.

[0032] Figure 5 This is an X-ray powder diffraction (XPRD) pattern of ASD prepared from NMN and Eudragit-70% in one embodiment of the present invention. The pattern confirms that NMN is an amorphous solid.

[0033] Figure 6The image shows a scanning electron microscope (SEM) image of ASD prepared from NMN and Eudragit-70% in one embodiment of the present invention. The top image is a 200x magnification image, and the bottom image is a 2000x magnification image. This image confirms that the NMN-based ASD is in a uniformly dispersed powder form.

[0034] Figure 7 This is a comparison of differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) plots of ASD prepared with NMN and Eudragit-70% in one embodiment of the present invention. The horizontal axis represents temperature (°C); the left vertical axis represents heat flow (W / g), and the right vertical axis represents weight percentage.

[0035] Figure 8 This is an X-ray powder diffraction pattern (XPRD pattern) of NMN-crystal form I in one embodiment of the present invention.

[0036] Figure 9 This is an X-ray powder diffraction pattern (XPRD pattern) of NMN-amorphous material in one embodiment of the present invention. Detailed Implementation

[0037] To address the shortcomings of NMN, such as poor stability, hygroscopicity, and rapid release in vivo, preparing it into an amorphous solid dispersion (ASD) formulation is a better option.

[0038] In solid dispersions, the dissolution rate of a drug largely depends on the properties of the carrier. The requirements for a carrier are: water solubility, physiological inertness, and non-toxicity; it should not chemically react with the drug or affect the chemical stability of the active pharmaceutical ingredient; it should easily achieve optimal drug dispersion; and it should be readily available and inexpensive.

[0039] In solid dispersion technology, commonly used carriers are broadly classified into water-soluble, poorly soluble, and enteric-coated types based on their solubility and drug release characteristics. Water-soluble carrier materials can improve drug solubility and dissolution rate, and are often used to prepare immediate-release solid dispersions; examples include polyethylene glycol, povidone, surfactants, and organic acids. Poorly soluble carrier materials can delay drug release and are used to prepare sustained-release solid dispersions; examples include ethyl cellulose, polyacrylic acid resins, and lipids. Enteric-coated carrier materials can control drug release at specific sites in the intestine, avoiding destruction in the stomach; examples include cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, and polyacrylic acid resins.

[0040] To address the aforementioned drawbacks of NMN, especially those of NMN crystals, and considering its weakly acidic nature and the medical / health requirements for controlled release into the human body, we compared and screened numerous solid dispersion carrier materials. Ultimately, we found that hydroxypropyl methylcellulose E5 (HPMC-E5), povidone K30 (PVP-K30), and 70% Eudragit dispersion (Eudragit-70%) are optimally compatible with amorphous NMN. Even with the addition of small amounts of additives such as the flavoring triethyl citrate, the amorphous form of NMN can be maintained.

[0041] Those skilled in the art should understand that the hydrophilic polymer carrier materials that can be used in the NMN amorphous solid dispersant of the present invention are not limited to the three types mentioned above, but also include other commonly used food and pharmaceutical safety carrier materials with the same or similar physical and chemical properties.

[0042] In the NMN amorphous solid dispersant, the weight ratio of NMN to hydrophilic polymer is 1:0.8-2.5, preferably 1:1-2, more preferably 1:1-1.8, and even more preferably 1:1-1.5. If the weight ratio is higher than 1:0.8, some amorphous NMN tends to form crystals; if the weight ratio of NMN to hydrophilic polymer is lower than 1:2.5, it may affect the intestinal dissolution rate of NMN.

[0043] In the embodiments, X-ray powder diffraction (XPRD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA) confirmed that the solid dispersion prepared by mixing HPMC-E5, PVP-K30, Eudragit-70%, or a mixture thereof with amorphous NMN and then spray-drying it could effectively maintain the amorphous state of NMN. Experiments at room temperature and under humid conditions confirmed that the amorphous solid dispersion of NMN had higher stability. Dissolution experiments confirmed that the amorphous solid dispersion of NMN had a sustained-release effect.

[0044] The present invention is further illustrated below by way of examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the invention.

[0045] Example

[0046] The examples involve the addition amount, content and concentration of various substances, and unless otherwise specified, the percentage content refers to the mass percentage content.

[0047] In the embodiments described herein, unless otherwise specified, the temperature generally refers to room temperature (15-30°C).

[0048] Reagents: The reactants and catalysts used in the embodiments of this invention are all chemically pure and can be used directly or purified as needed; organic solvents are all analytically pure and can be used directly. Hydroxypropyl methylcellulose, Eutrich, and other excipients were purchased from Anhui Shanhe Pharmaceutical Excipients Co., Ltd., and other reagents were purchased from Aladdin Chemical Reagent Co., Ltd.

[0049] The spray dryer used in the experiment was a YM-015 laboratory spray dryer manufactured by Shanghai Yuming Instrument Co., Ltd.

[0050] The homogenizer is a Shanghai Shangyi handheld high-speed homogenizer, model SN-GJR-18 (speed range: 10000~29700rpm). X-ray powder diffraction:

[0051] X-ray powder diffraction analysis was performed using CuKα rays on a Thermo Fisher Scientific powder X-ray diffractometer. The test power was 45 kV × 40 mA, the scanning speed was 5° / min, the step width was 0.02°, and the scanning range was 3–40° (2θ) with continuous scanning from θ to 2θ.

[0052] Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) characterization:

[0053] The measurements were performed using a TA Q2000 / 2500 differential scanning calorimeter under nitrogen protection, with a heating rate of 10 °C / min, and the temperature gradually increased from 25 °C to the set endpoint.

[0054] MRI scanner models: Bruker AV-500 and Bruker AV-600.

[0055] Example 1: Preparation of NMN amorphous solid dispersion using hydroxypropyl methylcellulose E5 (HPMC-E5) as a carrier

[0056] 10.0 g of hydroxypropyl methylcellulose E5 was added to 200 mL of 20% ethanol and homogenized at 10,000 rpm for 10 min. Then, 10.0 g of β-nicotinamide mononucleotide (NMN) was added and homogenized for another 5 min. The feed rate of the spray dryer was set to 8 mL / min, the pressure to 3 atm, the temperature to 130℃, and the fan to 100% airflow. The material was spray-dried. After spray drying, the material in the collection bottle was collected, yielding approximately 12.8 g of amorphous solid dispersion of β-nicotinamide mononucleotide NMN-HPMC-E5 dispersed in hydroxypropyl methylcellulose E5.

[0057] The obtained X-ray powder diffraction pattern (XPRD pattern) of NMN-HPMC-E5 is shown in the figure. Figure 1As can be seen from the figure, NMN-HPMC-E5 has no obvious absorption peaks and is in an amorphous state, that is, NMN-HPMC-E5 is an amorphous solid dispersion.

[0058] The resulting NMN-HPMC-E5 contained 3.5 wt% water and produced particles ranging from 1 to 20 μm, with most particles having a diameter ranging from 2 to 5 μm. Figure 2 ).

[0059] To test the dissolution rate of the NMN-HPMC-E5 amorphous solid dispersion, 6.0 g of the NMN-HPMC-E5 amorphous solid dispersion (NMN: HPMC = 1:1) was added to 33 mL of water at 25 °C and stirred with a paddle at 40 rpm. Every 10 min, the supernatant was collected, centrifuged, and the aqueous solution was analyzed to measure the NMN content (theoretically, 100% dissolved NMN content is 8.33%). For comparison, 3.0 g of NMN (crystal form I) was simultaneously added to 33 mL of water, and the NMN content was measured concurrently. The results are shown in Table 1. Figure 3 After 10 minutes, 96.4% of NMN-Crystal Form I had dissolved, almost all of it, while only 51.0% of NMN-HPMC-E5 had dissolved. After 90 minutes, 90.9% of NMN-HPMC-E5 had dissolved, indicating that the amorphous solid dispersion of NMN-HPMC-E5 has a sustained-release effect.

[0060] Table 1. Comparison of dissolution rates of ASD and NMN-Crystal Form I in NMN-HPMC-E5 (total dissolution content is 8.33%)

[0061] Time (min) NMN-HPMC-E5 dissolves NMN content (%) NMN-HPMC-E5 dissolution percentage NMN-Crystal Form I: NMN content dissolved (%) NMN-Crystal Form I Dissolution Percentage 0 0 0.0% 0 0.0% 10 4.25 51.0% 8.03 96.4% 20 5.33 64.0% 8.25 99.0% 30 5.8 69.6% 8.35 100.2% 40 6.11 73.3% 8.3 99.6% 50 6.56 78.8% 8.34 100.1% 60 6.88 82.6% 8.37 100.5% 90 7.57 90.9% 8.34 100.1%

[0062] Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) plots of NMN-HPMC-E5 are shown below. Figure 4 As shown, from room temperature to 500℃, the DSC and TGA curves of NMN-HPMC-E5 change relatively smoothly, without obvious endothermic or exothermic peaks, which is consistent with the characteristics of an amorphous state.

[0063] Example 2: Preparation of NMN amorphous solid dispersion using 70% Eudragit dispersion as a carrier

[0064] Add 28.0 g of 70% Eudragit dispersion to 200 mL of water, add 1.0 g of triethyl citrate while stirring, and stir until homogenized. Homogenize at 10,000 rpm for 10 min, then add 15.0 g of β-nicotinamide mononucleotide (NMN) and continue homogenizing for 5 min. Set the feed rate of the spray dryer to 8 mL / min, the temperature to 130℃, and the fan to 100% airflow. Spray dry the above material. After spray drying, collect the material in the collection bottle to obtain approximately 21.4 g of 70% Eudragit-dispersed β-nicotinamide mononucleotide amorphous solid dispersion NMN-Eudragit-70%.

[0065] The obtained X-ray powder diffraction pattern (XPRD pattern) of NMN-Eudragit-70% is shown in the image. Figure 5 As can be seen from the figure, NMN-Eudragit-70% has no obvious absorption peak and is in an amorphous state, that is, NMN-HPMC-E5 is an amorphous solid dispersion.

[0066] The resulting NMN-Eudragit-70% contained 2.2 wt% water and produced particles ranging from 1 to 20 μm, with most particles having a diameter ranging from 2 to 5 μm. Figure 6 ).

[0067] The differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) plots of the obtained NMN-Eudragit-70 are shown below. Figure 7 As shown in the DSC graph, there is a relatively obvious endothermic peak at 123℃, which may be the endothermic peak when Eudragit reaches its glass transition temperature; the TGA curve shows a gradual decrease without a very obvious step.

[0068] Example 3: Preparation of NMN amorphous solid dispersion using hydroxypropyl cellulose (HPC) as a carrier

[0069] 20.0 g of hydroxypropyl cellulose was added to 200 mL of 20% ethanol and homogenized at 10,000 rpm for 10 min. Then, 20.0 g of β-nicotinamide mononucleotide (NMN) was added and homogenized for another 5 min. The feed rate of the spray dryer was set to 8 mL / min, the temperature to 130℃, and the fan to 100% airflow. The material was spray-dried. After spray drying, the material in the collection bottle was collected, yielding approximately 33.7 g of hydroxypropyl cellulose-dispersed β-nicotinamide mononucleotide amorphous solid dispersion NMN-HPC.

[0070] Example 4: Preparation of NMN amorphous solid dispersant using polyvinylpyrrolidone K30 (PVP-K30) as a carrier

[0071] Add 15.0g of povidone K30 to 200mL of water, homogenize at 10000 rpm for 10min, then add 10.0g of β-nicotinamide mononucleotide (NMN) and homogenize for another 5min. Set the feed rate of the spray dryer to 8mL / min, the temperature to 130℃, and the fan to 100% airflow to spray dry the material. After spray drying, collect the material in the collection bottle to obtain approximately 18.6g of amorphous solid dispersion of β-nicotinamide mononucleotide NMN-PVP-K30 dispersed in povidone K30.

[0072] Example 5: Preparation of NMN amorphous solid dispersion using hydroxypropyl methylcellulose + Eudragit (HPMC + Eudragit) as a carrier

[0073] 6.0 g of hydroxypropyl methylcellulose was added to 200 mL of water, homogenized at 10,000 rpm for 10 min, then 5.7 g of 70% aqueous dispersion Eudragit and 0.4 g of triethyl citrate were added, and homogenization continued for another 10 min. Then, 10.0 g of β-nicotinamide mononucleotide (NMN) was added. The feed rate of the spray dryer was set to 8 mL / min, the temperature to 130℃, and the fan to 100% airflow. The above materials were spray-dried. After spray drying, the material in the collection bottle was collected, yielding approximately 15.7 g of an amorphous solid dispersion of β-nicotinamide mononucleotide NMN-HPMC+Eudragit, composed of hydroxypropyl methylcellulose and Eudragit.

[0074] Example 6: Stability test of NMN amorphous dispersion

[0075] Take 5.0g of each of the five samples prepared in Examples 1-5: NMN-HPMC-E5, NMN-Eudragit-70%, NMN-HPC, NMN-PVP-K30, and NMN-HPMC+Eudragit; take 5.0g of NMN crystal form I sample (prepared according to the method disclosed in patent document CN108697722B). Figure 8 The image shows the X-ray powder diffraction pattern (XPRD) for NMN-crystal form I. Then, 5.0 g of NMN sample was dissolved in 1.0 g of water and freeze-dried in a freeze dryer for 12 hours to obtain pure NMN amorphous powder. Figure 9 X-ray powder diffraction pattern (XPRD pattern) for NMN-amorphous detection.

[0076] The above 7 samples were sealed in double-layer PE and placed in a stability chamber for a week. They were subjected to room temperature stability test (temperature 25℃, RH=60%) and accelerated stability test (temperature 40℃, RH=75%). The appearance of the products was observed and the purity, content, moisture and other indicators were measured. The results are shown in Table 2 and Table 3 respectively.

[0077] Table 2. Room temperature stability test of NMN amorphous dispersion (temperature 25℃, RH=60%)

[0078]

[0079] As shown in Table 2, the stability of the five NMN amorphous dispersions in the room temperature stability test (temperature 25℃, RH=60%) was good, and the stability was not much different from that of NMN crystal form I; however, the stability of the NMN-amorphous dispersion without dispersant was poor, with a purity decrease of 18% and a moisture increase of 9% after 7 days, turning from a white powder into white lumps.

[0080] Table 3. Accelerated stability test of NMN amorphous dispersion (temperature 40℃, RH=75%)

[0081]

[0082] As shown in Table 3, the stability of the five NMN amorphous dispersions in the accelerated stability test (temperature 40℃, RH=75%) was good, and the stability was not much different from that of NMN crystal form I; however, the stability of the NMN-amorphous dispersion without dispersant was poor, with a 53% decrease in purity and a 23% increase in moisture after 7 days, turning from a white powder into a viscous liquid.

[0083] The specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art can make various modifications or variations within the scope of the claims. These modifications or variations do not affect the essence of the present invention and should all be included within the scope of the present invention.

Claims

1. An NMN amorphous solid dispersant, characterized in that, Its components mainly include food-grade or pharmaceutical-grade hydrophilic polymer powder particles and β-nicotinamide mononucleotide (NMN) embedded in the particles. Preferably, the NMN amorphous solid dispersant is mainly composed of food-grade or pharmaceutical-grade hydrophilic polymer powder particles and NMN embedded in the particles.

2. The NMN amorphous solid dispersant according to claim 1, characterized in that, The hydrophilic polymer is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (PVP), Eudragit dispersion, and mixtures of two or more thereof.

3. The NMN amorphous solid dispersant according to claim 2, characterized in that, The hydroxypropyl methylcellulose (HPMC) is hydroxypropyl methylcellulose E5 (HPMC-E5); the povidone (PVP) is povidone K30 (PVP-K30); and the Eudragit dispersion is 70% Eudragit dispersion (Eudragit-70%).

4. The NMN amorphous solid dispersant according to claim 1, characterized in that, The weight ratio of NMN to hydrophilic polymer is 1:0.8-2.5, preferably 1:1-2, more preferably 1:1-1.8, and even more preferably 1:1-1.

5.

5. The NMN amorphous solid dispersant according to claim 1, characterized in that, The water content in the NMN amorphous solid dispersant is no more than 5% by weight, preferably no more than 4.5%, and more preferably no more than 4%.

6. The NMN amorphous solid dispersant according to claim 1, characterized in that, The particle size of the NMN amorphous solid dispersant is not higher than 30 μm, preferably not higher than 25 μm, more preferably 0.5~22 μm, and even more preferably 1~20 μm; and / or The particle size D50 of more than 50%, preferably more than 60%, more preferably more than 70%, more preferably more than 80%, and more preferably more than 90% is 1-6μm, preferably 1.5-5.5μm, and more preferably 2-5μm.

7. A method for preparing the NMN amorphous solid dispersant according to any one of claims 1-6, characterized in that, Includes the following steps: (1) Raw material preparation: Dissolve the hydrophilic polymer in water or an aqueous ethanol solution to obtain a hydrophilic polymer dilution; (2) Raw material mixing: NMN is added to the hydrophilic polymer dilution solution and mixed evenly to obtain a mixture. (3) The mixture obtained in step (2) is formed into powder particles by spray drying device.

8. The method according to claim 7, characterized in that, Step (1) is to obtain a hydrophilic polymer dilution by homogenization using a homogenizer; Step (2) is to obtain a mixture by homogenization using a homogenizer.

9. The method according to claim 7, characterized in that, The spray drying temperature is not higher than 150°C, preferably not higher than 140°C, more preferably not higher than 135°C, and even more preferably not higher than 130°C.

10. Use of the NMN amorphous solid dispersion according to any one of claims 1-6 in the preparation of food, dietary supplements and / or pharmaceuticals.

Images